GlassScriptPhysician profile
Meena Farid
NPI 1407438260
$3,722.07
in general payments reported to CMS, 2019-2025
18 companies · $3,135 in 2025
The $3,135 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.41 · 2024: $574 · 2025: $3,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707 · Travel and Lodging: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.22 |
| Travel and Lodging | $1,014.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,336.22 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Abbott Laboratories | $351.17 | 2025 | Cardiomems, Gallant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $335.60 | 2024-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $321.38 | 2024-2025 | Assure Wcd |
| Penumbra, INC. | $275.25 | 2025 | Indigo System |
| Boston Scientific Corporation | $235.47 | 2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Angiodynamics, INC. | $159.41 | 2025 | Alphavac |
| Astrazeneca Pharmaceuticals LP | $150.60 | 2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $114.13 | 2024-2025 | Amvuttra |
| Abbvie INC. | $85.20 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.66 | 2023-2025 | Camzyos, Eliquis |
| Abiomed | $61.97 | 2025 | |
| Pfizer INC. | $61.59 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.22 | 2025 | |
| Bracco Diagnostics INC. | $38.24 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $29.98 | 2025 | |
| Eisai INC. | $28.46 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $22.52 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Farid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.